BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8158041)

  • 1. Long-acting therapy of viral retinitis with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine.
    Flores-Aguilar M; Huang JS; Wiley CA; De Clercq E; Vuong C; Bergeron-Lynn G; Chandler B; Munguia D; Freeman WR
    J Infect Dis; 1994 Mar; 169(3):642-7. PubMed ID: 8158041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposome-encapsulated (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for long-acting therapy of viral retinitis.
    Kuppermann BD; Assil KK; Vuong C; Besen G; Wiley CA; De Clercq E; Bergeron-Lynn G; Connor JD; Pursley M; Munguia D; Freeman WR
    J Infect Dis; 1996 Jan; 173(1):18-23. PubMed ID: 8537656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term therapy for herpes retinitis in an animal model with high-concentrated liposome-encapsulated HPMPC.
    Besen G; Flores-Aguilar M; Assil KK; Kupperman BD; Gangan P; Pursley M; Munguia D; Vuong C; De Clercq E; Bergeron-Lynn G
    Arch Ophthalmol; 1995 May; 113(5):661-8. PubMed ID: 7748139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).
    Snoeck R; Andrei G; Gérard M; Silverman A; Hedderman A; Balzarini J; Sadzot-Delvaux C; Tricot G; Clumeck N; De Clercq E
    Clin Infect Dis; 1994 Apr; 18(4):570-8. PubMed ID: 8038312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of retinal toxicity of the anticytomegalovirus drug (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine.
    Dolnak DR; Munguia D; Wiley CA; De Clercq E; Bergeron-Lynn GL; Boscher C; Connor JD; Sherwood C; Capparelli E; Armani R
    Invest Ophthalmol Vis Sci; 1992 Apr; 33(5):1557-63. PubMed ID: 1559752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged and potent therapeutic and prophylactic effects of (S)-1-[(3-hydroxy-2-phosphonylmethoxy)propyl]cytosine against herpes simplex virus type 2 infections in mice.
    Yang H; Datema R
    Antimicrob Agents Chemother; 1991 Aug; 35(8):1596-600. PubMed ID: 1929331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS.
    De Castro LM; Kern ER; De Clercq E; Ghaffar A; Mayer EP; Vogt PE; Gangemi JD
    Antiviral Res; 1991 Jul; 16(1):101-14. PubMed ID: 1663726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in various models of herpes simplex virus infection in mice.
    De Clercq E; Holý A
    Antimicrob Agents Chemother; 1991 Apr; 35(4):701-6. PubMed ID: 2069375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of Cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections.
    De Clercq E
    Verh K Acad Geneeskd Belg; 1996; 58(1):19-47; discussion 47-9. PubMed ID: 8701600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anterior nongranulomatous uveitis after intravitreal HPMPC (cidofovir) for the treatment of cytomegalovirus retinitis. Analysis and prevention.
    Chavez-de la Paz E; Arevalo JF; Kirsch LS; Munguia D; Rahhal FM; De Clercq E; Freeman WR
    Ophthalmology; 1997 Mar; 104(3):539-44. PubMed ID: 9082286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG).
    Neyts J; Snoeck R; Schols D; Balzarini J; De Clercq E
    Virology; 1990 Nov; 179(1):41-50. PubMed ID: 2171213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective treatment of experimental cytomegalovirus-induced encephalo-meningitis in immunocompromised rats with HPMPC.
    Kloover JS; Vanagt WY; Stals FS; Bruggeman CA
    Antiviral Res; 1997 Jul; 35(2):105-12. PubMed ID: 9217247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic developments in cytomegalovirus retinitis.
    Hoffman VF; Skiest DJ
    Expert Opin Investig Drugs; 2000 Feb; 9(2):207-20. PubMed ID: 11060672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice.
    Neyts J; Sobis H; Snoeck R; Vandeputte M; De Clercq E
    Eur J Clin Microbiol Infect Dis; 1993 Apr; 12(4):269-79. PubMed ID: 8390357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome.
    Kirsch LS; Arevalo JF; Chavez de la Paz E; Munguia D; de Clercq E; Freeman WR
    Ophthalmology; 1995 Apr; 102(4):533-42; discussion 542-3. PubMed ID: 7724170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs.
    Li SB; Yang ZH; Feng JS; Fong CK; Lucia HL; Hsiung GD
    Antiviral Res; 1990 May; 13(5):237-52. PubMed ID: 2168690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose intravitreal cidofovir (HPMPC) therapy of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome.
    Taskintuna I; Rahhal FM; Arevalo JF; Munguia D; Banker AS; De Clercq E; Freeman WR
    Ophthalmology; 1997 Jun; 104(6):1049-57. PubMed ID: 9186448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of HPMPC therapy for primary and recurrent genital herpes in mice and guinea pigs.
    Bravo FJ; Stanberry LR; Kier AB; Vogt PE; Kern ER
    Antiviral Res; 1993 May; 21(1):59-72. PubMed ID: 8391249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rat cytomegalovirus-induced pneumonitis after allogeneic bone marrow transplantation: effective treatment with (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine.
    Stals FS; Zeytinoglu A; Havenith M; de Clercq E; Bruggeman CA
    Antimicrob Agents Chemother; 1993 Feb; 37(2):218-23. PubMed ID: 8383939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice.
    Neyts J; Balzarini J; Naesens L; De Clercq E
    J Med Virol; 1992 May; 37(1):67-71. PubMed ID: 1320099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.